Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma
Public ClinicalTrials.gov record NCT00069758. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center Phase II Study to Investigate the Safety and Activity of SDX-105 (Bendamustine) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab
Study identification
- NCT ID
- NCT00069758
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Cephalon
- Industry
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Interventions
- SDX-105 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2003
- Primary completion
- Mar 31, 2007
- Completion
- Mar 31, 2007
- Last update posted
- May 8, 2014
2003 – 2007
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294-3300 | — |
| Comprehensive Cancer Center-Desert Regional Medical Center | Palm Springs | California | 92262 | — |
| San Diego Cancer Center | Vista | California | 92083 | — |
| Georgetown University Medical Center - Lombardi Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| Mountain States Tumor Institute | Boise | Idaho | 83712 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| The Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| The Sarah Cannon Cancer Center | Nashville | Tennessee | 37203 | — |
| Southwest Regional Cancer Center | Austin | Texas | 78705 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Virginia Medical Center | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00069758, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2014 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00069758 live on ClinicalTrials.gov.